ESMO 2017 Highlights in Basic Science: Impressive Research by Young Investigators

Speaker: Anton Berns

Abudlah Alajati’s research goes beyond controversy, to explain the role of CDCP1 receptor in prostate cancer progression. This protein load is a Biomarker for prostate cancer aggressiveness and we now need to learn if the use of a Receptor inhibitor would slow the progression of these cancers in patients as it does in vitro.

Anton Berns explains that the EACR and ESMO partnership in this congress is welcome as research and clinical practice need each other. His selection of studies from very promising young investigators shows the interest of what they are doing in the field.

Sumanta Pal reports results from one of the largest cohorts of patients assessed by cell-free DNA and shows that 84% of the patients had detectable cell-free DNA in their blood. The method is able to identify rare Mutations and the presence of multiple actionable alterations. The viability of the method to identify viable therapy was demonstrated.

Abudlah Alajati’s research goes beyond controversy, to explain the role of CDCP1 receptor in prostate cancer progression. This protein load is a Biomarker for prostate cancer aggressiveness and we now need to learn if the use of a Receptor inhibitor would slow the progression of these cancers in patients as it does in vitro.

Abstracts

  • 1702O - Clinical implications of genomic variants identified in over 30,000 advanced-stage cancer patients by next-generation sequencing of circulating tumor DNA
  • 2O - CDCP1 initiates tumorigenesis and cooperates with PTEN loss to promote senescence evasion and prostate cancer progression

More resources from ESMO 2017 Congress